Name
FOLFIRI
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for FOLFIRI
Name
Alternate Names
Ziv-Aflibercept
Abbreviations
None
Category
Chemotherapy
Subcategory
Angiogenesis inhibitor
NSC Number
None
Primary Site
Colorectal
Histology
None
Remarks
The FDA approved Zaltrap for use in combination with a FOLFIRI chemotherapy regimen on August 3, 2012.
Coding
This drug should be coded
Name
Alternate Names
5-Fluorouracil
5-Fluracil
Adrucil
Efudex
Fluoroplex
Fluracil
Fluril
Oracil
Ro 2-9757
WR-69596
Abbreviations
5-FU
5FU
FU
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
019893
19893
Primary Site
Breast- adjuvant setting and advanced disease
colorectal- adjuvant setting and advanced disease
GI malignancies: anal, esophageal, gastric and pancreatic
Hepatoma
Ovarian cancer
Histology
None
Remarks
Fluorinated pyrimidine; antimetabolite. FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Coding
This drug should be coded
Name
Alternate Names
Calcium folinate
Calcium leucovorin
Calcium leucovorin rescue
Citrovorum Factor
Citrovorum factor rescue
Folic acid
Folinic Acid
Lederfoline
Leucosar
Leucovorin Calcium
Leucovorin rescue
Wellcovorin
Abbreviations
C.F.
CF
CL
Category
Ancillary Agent
Subcategory
None
NSC Number
3590
003590
Primary Site
None
Histology
None
Remarks
The pharmacologically active form of folic acid. FDA approved uses as 1st line colorectal carcinoma in combination with 5-FU and to diminish methotrexate toxicity.
Coding
This drug should NOT be coded
Name
Alternate Names
Camptosar
Camptosar Oral
Camptothecin-11
CPT 11
CPT-11
CPT11
U-101440E
Abbreviations
None
Category
Chemotherapy
Subcategory
Topoisomerase inhibitor
NSC Number
616348
Primary Site
Colorectal
head & neck
Non-small cell lung cancer (NSCLC)
pancreatic cancer
Small cell lung cancer (SCLC)
Histology
None
Remarks
Phase I (head & neck) Phase III SCLC pancreatic Topoisomerase I inhibitor. FDA approved use on colorectal cancer. Pharmacia.
Coding
This drug should be coded